Clinical experience with apremilast for psoriatic arthritis
The novel targeted synthetic disease-modifying antirheumatic drug apremilast (AP), a phosphodiesterase 4 inhibitor, is currently used to treat psoriasis and psoriatic arthritis (PsA). AP treatment can reduce the level of proinflammatory cytokines and the activity of inflammatory changes. The article...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/850 |